Modern healthcare innovation is increasingly focused on the patient experience. In respiratory medicine, this means looking beyond the development of medicines to consider how treatments are delivered and how easily patients can incorporate them into their daily routines.
Respiratory conditions such as asthma, COPD, allergic rhinitis and other airway diseases can require ongoing management, making convenience and treatment adherence important considerations.
What Is Patient-Centric Respiratory Care?
Patient-centric healthcare places the needs and experiences of patients at the centre of treatment development.
In respiratory medicine, this can involve developing therapies with appropriate delivery systems, clear administration requirements and practical considerations for everyday use.
The Importance of Treatment Delivery
Respiratory medicines can be delivered through different technologies, including inhalers, nasal sprays and nebulisation systems.
Each delivery method has its own characteristics. The choice of treatment and device depends on the medical condition, prescribed therapy and individual patient circumstances.
Making Respiratory Treatment More Practical
Ease of use can be an important consideration in respiratory care. If a delivery device is difficult to use, patients may have challenges following their prescribed treatment correctly.
For this reason, pharmaceutical innovation increasingly considers the interaction between medicine, device and patient.
Glenmark's respiratory portfolio includes DPIs, MDIs, nasal sprays and nebulisation technologies, reflecting the need for different delivery approaches across respiratory conditions.
Innovation in Allergic Rhinitis
Allergic rhinitis is an example of a condition where treatment can involve addressing multiple aspects of the disease.
Glenmark's Ryaltris® is a fixed-dose nasal spray combining an antihistamine and corticosteroid. The company describes the product as addressing both the allergic response and underlying nasal inflammation.
Supporting Long-Term Respiratory Care
For chronic conditions such as asthma and COPD, treatment may form part of long-term disease management.
Patient-centred innovation can help ensure that pharmaceutical development considers not only clinical outcomes but also convenience, administration and adherence.
The Role of Pharmaceutical Companies
Pharmaceutical companies have an important role in developing new therapies and delivery technologies supported by scientific and clinical evidence.
Glenmark's respiratory franchise spans chronic respiratory diseases as well as cough, rhinitis and allergies. Its stated approach combines clinical research, differentiated therapies and delivery technologies.
Looking Toward the Future
Respiratory healthcare will continue to evolve as pharmaceutical research and medical technology advance.
The future may bring further improvements in medicines, formulations, devices and delivery systems. Keeping patient needs at the centre of this innovation can help ensure that advances in respiratory medicine translate into practical healthcare solutions.
Reference: Glenmark Pharmaceuticals – Respiratory
https://glenmarkpharma.com/respiratory/
This article is intended for general educational purposes and should not replace consultation with a qualified healthcare professional.
Sign in to leave a comment.